Inmune Bio (INMB) Total Current Liabilities (2018 - 2025)
Inmune Bio (INMB) has disclosed Total Current Liabilities for 8 consecutive years, with $8.4 million as the latest value for Q4 2025.
- Quarterly Total Current Liabilities rose 16.55% to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, up 16.55% year-over-year, with the annual reading at $8.4 million for FY2025, 16.55% up from the prior year.
- Total Current Liabilities hit $8.4 million in Q4 2025 for Inmune Bio, up from $7.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $18.5 million in Q4 2023 to a low of $2.2 million in Q1 2021.
- Historically, Total Current Liabilities has averaged $9.0 million across 5 years, with a median of $8.2 million in 2025.
- Biggest five-year swings in Total Current Liabilities: skyrocketed 471.33% in 2023 and later crashed 60.89% in 2024.
- Year by year, Total Current Liabilities stood at $4.4 million in 2021, then soared by 150.47% to $10.9 million in 2022, then surged by 69.12% to $18.5 million in 2023, then plummeted by 60.89% to $7.2 million in 2024, then grew by 16.55% to $8.4 million in 2025.
- Business Quant data shows Total Current Liabilities for INMB at $8.4 million in Q4 2025, $7.4 million in Q3 2025, and $8.6 million in Q2 2025.